Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib

Cholangiocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of 11–44% after surgical resection. However, there is no established systemic therapy after failure of the gemcitabine plus cisplatin first-line therapy with exception of FOLFOX. Fibroblast growth factor receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, James, Mahipal, Amit, Kim, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550543/
https://www.ncbi.nlm.nih.gov/pubmed/34720591
http://dx.doi.org/10.2147/OTT.S272208